Bank of Hawaii lessened its stake in shares of Sanofi SA (NYSE:SNY) by 14.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 43,038 shares of the company’s stock after selling 7,218 shares during the period. Bank of Hawaii’s holdings in Sanofi were worth $1,722,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in the stock. HL Financial Services LLC boosted its stake in Sanofi by 25.3% during the first quarter. HL Financial Services LLC now owns 17,760 shares of the company’s stock worth $712,000 after buying an additional 3,587 shares during the last quarter. Wells Fargo & Company MN raised its position in Sanofi by 2.2% in the first quarter. Wells Fargo & Company MN now owns 2,697,787 shares of the company’s stock valued at $108,128,000 after purchasing an additional 57,855 shares during the period. Wealthstreet Investment Advisors LLC raised its position in Sanofi by 26.0% in the first quarter. Wealthstreet Investment Advisors LLC now owns 11,392 shares of the company’s stock valued at $457,000 after purchasing an additional 2,350 shares during the period. Commerzbank Aktiengesellschaft FI raised its position in Sanofi by 107.1% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 45,244 shares of the company’s stock valued at $1,813,000 after purchasing an additional 23,399 shares during the period. Finally, Pekin Singer Strauss Asset Management IL purchased a new stake in Sanofi in the first quarter valued at $1,485,000. Institutional investors own 7.54% of the company’s stock.
Shares of SNY stock traded down $0.66 on Friday, hitting $42.85. The stock had a trading volume of 644,800 shares, compared to its average volume of 2,012,102. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $109.35 billion, a PE ratio of 13.66, a P/E/G ratio of 2.27 and a beta of 0.90. Sanofi SA has a 1 year low of $37.43 and a 1 year high of $50.65.
SNY has been the topic of a number of research analyst reports. Citigroup upgraded Sanofi from a “neutral” rating to a “buy” rating in a research report on Friday, August 10th. ValuEngine downgraded Sanofi from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 2nd. Zacks Investment Research upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Wednesday, June 13th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Tuesday, July 31st. Finally, Deutsche Bank restated a “buy” rating on shares of Sanofi in a research report on Wednesday, August 1st. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $47.00.
In related news, major shareholder Sanofi sold 121,601 shares of the business’s stock in a transaction on Friday, June 8th. The stock was sold at an average price of $309.31, for a total value of $37,612,405.31. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.00% of the stock is currently owned by insiders.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: Return on Investment (ROI)
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.